Globus Medical is a medical device company located in Pennsylvania, United States, which is part of the Healthcare sector, and is traded under the ticker GMED on the NYSE exchange.
Globus Medical stock last closed at $86.70, down 2.45% from the previous day, and has increased 4.82% in one year. It has overperformed other stocks in the Medical Devices industry by 0.37 percentage points. Globus Medical stock is currently +67.41% from its 52-week low of $51.79, and -8.67% from its 52-week high of $94.93.
There are currently 133.84M GMED shares outstanding. The market value of GMED is $11.60B. In the last 24 hours, 1.4M GMED shares were traded.
You need a brokerage account to access the NYSE market and buy GMED shares.
Based on our research, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your stock purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, you'll need to fill out some personal information so you can buy GMED today.
Now that you've filled out your info on apps for stock market, your next step is to transfer the money for your investment:
Watch the walkthrough below for more details depositing money into your new brokerage account.
Once you have decided on the best place to buy Globus Medical stock, it's critical to analyze their stock prior to investing, so you actually wrap your head around the risk as well as the upside.
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on GMED's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge GMED's fair value.
Using relative valuations methods:
You can access additional valuation analysis on GMED's stock here.
Out of 8 sell side analysts who give recommendations on GMED, the consensus analyst rating on Globus Medical is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
Craig Bijou, a top 8% analyst from Bank of America upgrades GMED to a strong buy rating and raises their GMED price target from $65.00 to $91.00, on Nov 7, 2025.
Bank of America's Craig Bijou upgraded their rating on Globus Medical (NYSE: GMED) from Hold to Strong Buy on 2025/11/07. The analyst also raised their price target by 40% from $65 to $91.
Globus Medical reported its Q3 2025 earnings.
Upgrading the stock and hiking their price target, Bijou headlined that the quarter set records for revenue, earnings, and cash flow.
The analyst specifically cited Globus Medical's capacity to deliver compounded profits and cash flow for their upgrade from Hold to Strong Buy.
The stock's valuation is "not stretched" at current levels, Bijou told readers.
For Q3 2025, Globus Medical reported:
Management did not provide financial guidance in its press release.
President & CEO Keith Pfeil reported: “We are pleased with the strength of our overall results and continued progress throughout the company.
“Q3 revenue rose 23%, driven by 10% growth in our US Spine business, as momentum accelerated during the quarter with broad-based demand across our products and geographies.
"Our recently acquired Nevro business continued to exceed expectations, underscoring the strength of our integration strategy, as we position this business for future growth.
"Strength in revenue translated into enhanced earnings and profitability, with meaningful improvements in adjusted gross margins and operating expenses, reflecting both synergy capture and operating leverage from the NuVasive merger and Nevro acquisition.
"Looking ahead, we remain focused on finishing 2025 strong, with a clear path toward consistent organic growth through innovation, disciplined execution, and delivering differentiated technologies that improve patient outcomes.”
Thomas Stephan, a top 21% analyst from Stifel Nicolaus reinstates GMED with a hold rating and announces their GMED price target of $64.00, on Oct 28, 2025.
William Plovanic, a top 11% analyst from Canaccord Genuity maintains GMED with a strong buy rating and lowers their GMED price target from $97.00 to $90.00, on Jul 22, 2025.
You can dig deeper into what analysts are saying on the Globus Medical stock forecast page.
Last year, GMED earnings were $423.78M. During the past five year, GMED's earnings have grown by 26.66% per year. This was faster than the Medical Devices industry average of 14.21%.
Last year, GMED revenue was $2.77B. In the last 5 year, GMED's revenue has increased by 29.27% per year. This was faster than the Medical Devices industry average of 10.92%.
Dig into GMED's earnings and revenue performance here.
Over the last year, executives and large shareholders at GMED have bought more shares than they have sold.
David C. Paul, Executive Chairman of GMED, was the latest GMED insider to buy. They bought $877,250.00 worth of GMED stock on Dec 8, 2025.
Research more about who owns GMED stock here.
No, Globus Medical doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
There are two main order types:
Click the Open button and eToro will execute the order.
If you require additional assistance investing in stocks on eToro, watch the how to video below:
Now that you own some GMED stock, you'll want to keep up with your investment.
Create a watchlist to track the most important metrics related to your GMED stock.
To reiterate, here are the 6 steps you need to take to buy Globus Medical stock right now:
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your investment in Globus Medical, click below.